News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
News Novartis less exposed to US pricing pressure, says Jimenez Europe and Asia account for a large share of company's income.
News Biogen protects Tecfidera via $1.25bn deal with Forward Biogen could also pay royalties to Forward.
UK & Europe Pfizer's Lyrica patent appeal fails in UK Generics firms free to exploit gap in Pfizer's patent defences.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
